Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.
We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150-200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.
Fossella
F V
FV
Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston.
Winn
R J
RJ
Holoye
P Y
PY
Hallinan
B
B
Raber
M N
MN
Hoelzer
K
K
Young
J A
JA
Readling
J
J
Bowers
B
B
Hong
W K
WK
D000328:Adult; D000368:Aged; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016597:Trimetrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D016597:Trimetrexate